---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-000084"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:19:30.577963+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics enters $100M upfront collaboration with Novartis for SMA and HD gene therapy

## Summary
- Voyager Therapeutics entered into a license and collaboration agreement with Novartis for AAV capsids for SMA and Huntington's disease programs, with $80M upfront payment and $20M stock purchase.
- Voyager eligible for up to $200M in milestones for SMA program and $225M for HD program, plus sales milestones and tiered royalties.
- Voyager estimates preliminary cash of $230.7M as of Dec 31, 2023; adjusted to $330.7M after anticipated $100M upfront from Novartis.
- Voyager plans to submit IND for VY-TAU01 (Alzheimer's) in first half 2024 and for SOD1 ALS gene therapy in mid-2025.
- Voyager entered into a stock purchase agreement and investor agreement with Novartis, including standstill and lock-up restrictions.

## SEC filing metadata
- accession: 0001104659-24-000084
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/0001104659-24-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/tm241304d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-000084
- JSON: https://secwatch.observer/filing/0001104659-24-000084.json
- Plain text: https://secwatch.observer/filing/0001104659-24-000084.txt

## Key facts
- Material Agreements
  Voyager Therapeutics, Inc. entered into License and Collaboration Agreement with Novartis Pharma AG valued at $80 million (effective 2023-12-28).
  - Action: entry
  - Agreement: license
  - Counterparty: Novartis Pharma AG
  - Value: $80 million
  - Effective: 2023-12-28
  source text: On December 28, 2023 (the “Effective Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”) with Novartis Pharma AG (“Novartis”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/0001104659-24-000084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.